Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Its lead product candidate is ETC-1002 or Bempedoic acid, an inhibitor of ATP Citrate Lyase, an enzyme on the cholesterol biosynthesis pathway that is in Phase III long-term safety and tolerability study to treat patients with hypercholesterolemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol, and up-regulates LDL-receptors, resulting in increased LDL-C clearance and reduced plasma levels of LDL-C. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
I was watching this stock last month waiting to see a solid move over $14, it could not do it. $12 support, $14 resistance is the current range here.
Shares of Esperion Therapeutics (ESPR) jumped 32.2% to $31.30 after the Ann Arbor, Mich.-based lipid management company said the U.S. Food and Drug Administration"recently confirmed that Esperion's LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid." Esperion said it intends to submit a new drug application by the first half of 2019 for an LDL-C lowering indication based on the successful completion of the phase three clinical development program.
WTH, I was hoping to get back in at some point after the 20% drop last Friday, guess I am too late now
Daytraders having a field day here. You know, when daily shares traded matches total # of shares, you can see 100% moves in a day. And it's only 65% right now lol.
Crazy! I used to love trading stuff like this, but then I got older and more cautious. How about that GE? Great company!
Yeah we missed 10% The problem with trading stuff like this is when you only trade stuff like this. GE is amazing. Been in the Dow a long time.
Shares of Esperion Therapeutics (ESPR) may see early strength after the lipid management company said the FDA confirmed that its LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid.
$ESPR price target raised to $50 from $22 at JPMorgan, citing the company's "positive" regulatory update on bempedoic acid.
Esperion's Combo Cholesterol Candidate Enters Phase III - https://finance.yahoo.com/news/esperion-apos-combo-cholesterol-candidate-143002782.html
I received this stock recommendation today from a friend with considerable professional experience in financial services. It's a pharmaceutical company whose major product is being approved and rolled out worldwide - a drug that is used to control cholesterol, which is a major health concern for many. Their new drug, Nexletol, is better than Lipitor because many people are allergic to statins, of which Lipitor is. They just gained FDA and EU commission approval and have a major potential revenue incoming, which will only increase as COVID subsides. ESPR was driven down hard by COVID, and just now trading above its 52 week low. But here's the interesting part - He says institutions hold 122% of the shares and there is 42% short interest (as of Dec. 15th), a large majority of the institutional shares are likely in index funds that are not traded. If there is a squeeze, he says there is maybe 30% of the float in discretionary hands for the 42% shorts to buy back - so they might find it difficult to find shares to cover - they could get burned pretty badly in a squeeze. Institutions have likely accumulated even more since 12/15 and there are even less shares to cover a short. A considerable amount of that short is probably in option desks, and if you check out the options charts and you will a grossly disproportionate amount of calls. Current trading price (as of last close) is $28.92 (a little over 1/3 the 52 week high) and the the analysts mentioned in my various trading/research accounts have price targets from $35 to $150, with an average of $63-74. Different ranking services have this as a Buy or Strong Buy. Looking at the charts, the Daily Price Rate of Change is accelerating. A big piece of news could double this in a week given it's modest market cap. What is he/am I missing?
